NGM Biopharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview

NGM Biopharmaceuticals

30/10/2023 12:56

* NGM Biopharmaceuticals Inc  NGM.OQ   NGM.O  is expected
to show
a fall in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 69.0% decrease in revenue to $2.455 million from $7.91
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for NGM
Biopharmaceuticals
Inc is for a loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $6​, above​ its last closing price
of $0.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.50       -0.50      -0.46     Beat    7.6
 Mar. 31 2023  -0.53       -0.52      -0.58     Missed  -12.2
 Dec. 31 2022  -0.52       -0.51      -0.45     Beat    12.6​
 Sep. 30 2022  -0.60       -0.59      -0.59     Met     0.3
 ​​Jun.        -0.56       -0.55      -0.59     Missed  -7.3
 30 2022                                                
 Mar. 31 2022  -0.41       -0.46      -0.42     Beat    8.3​
 Dec. 31 2021  -0.35       -0.36      -0.35     Beat    2.8
 Sep. 30 2021  -0.37       -0.35      -0.37     Missed  -5.7
 This summary was machine generated October 30 at 12:56 GMT.  All
figures in US dollars  unless otherwise stated